One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the ...

The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.

Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA ...

Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?

Marty Makary's resignation leaves the agency with temporary directors in three top positions, and a number of newly ...

A pair of trial results published in medical journals suggest switching from high-dose injectables to lower doses or pills could help people with obesity keep their weight down over the long term.

Cell and gene therapies aren’t limited by ideas—they’re limited by where they’re built. See how “ready-now” locations change ...

It’s easy to assume that more data = better models = faster identification. With AI, you can extract associations between ...

Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.

Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with ...

The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese ...

While the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations. Entrada shares ...